The Once and Future Gene Therapy

Overview

Journal Nat Commun

Specialty Biology

Date 2020 Nov 17

PMID 33199717

Citations 102

Authors

Karen Bulaklak

Charles A Gersbach

Affiliations

Soon will be listed here.

Citing Articles

Triumphs, Trials, and Future Considerations in Genetic Therapies for Hereditary Neuromuscular Diseases.

Arnold W, Majithia K Mo Med. 2025; 122(1):46-52.

PMID: 39958595 PMC: 11827653.

Osteosarcoma: A comprehensive review of model systems and experimental therapies.

Robbins G, Vue Y, Rahrmann E, Moriarity B Med Res Arch. 2025; 12(11).

PMID: 39916749 PMC: 11801376. DOI: 10.18103/mra.v12i11.6000.

DNA-loaded targeted nanoparticles as a safe platform to produce exogenous proteins in tumor B cells.

Grimaldi M, Bozzer S, Sjostrom D, Andersson L, Mollnes T, Nilsson P Front Immunol. 2025; 15:1509322.

PMID: 39911576 PMC: 11794205. DOI: 10.3389/fimmu.2024.1509322.

Comparative Study of Functionalized Carbosilane Dendrimers for siRNA Delivery: Synthesis, Cytotoxicity, and Biophysical Properties.

Mullerova M, Tarach P, Strasak T, Curinova P, Petrickovic R, Zavodna T ACS Omega. 2025; 10(1):1047-1060.

PMID: 39829590 PMC: 11740622. DOI: 10.1021/acsomega.4c08314.

Leveraging plant-derived nanovesicles for advanced nucleic acid-based gene therapy.

Chai M, Gao B, Wang S, Zhang L, Pei X, Yue B Theranostics. 2025; 15(1):324-339.

PMID: 39744221 PMC: 11667239. DOI: 10.7150/thno.104507.

References

Maeder M, Stefanidakis M, Wilson C, Baral R, Barrera L, Bounoutas G . Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019; 25(2):229-233. DOI: 10.1038/s41591-018-0327-9. View

Dey G, Jaimovich A, Collins S, Seki A, Meyer T . Systematic Discovery of Human Gene Function and Principles of Modular Organization through Phylogenetic Profiling. Cell Rep. 2015; 10(6):993-1006. PMC: 5016211. DOI: 10.1016/j.celrep.2015.01.025. View

Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus M . Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010; 21(6):704-12. DOI: 10.1089/hum.2009.182. View

Thompson A, Walters M, Kwiatkowski J, Rasko J, Ribeil J, Hongeng S . Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. N Engl J Med. 2018; 378(16):1479-1493. DOI: 10.1056/NEJMoa1705342. View

Kim J, Hu C, El Achkar C, Black L, Douville J, Larson A . Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. N Engl J Med. 2019; 381(17):1644-1652. PMC: 6961983. DOI: 10.1056/NEJMoa1813279. View

Anzalone A, Koblan L, Liu D . Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020; 38(7):824-844. DOI: 10.1038/s41587-020-0561-9. View

Hnisz D, Abraham B, Lee T, Lau A, Saint-Andre V, Sigova A . Super-enhancers in the control of cell identity and disease. Cell. 2013; 155(4):934-47. PMC: 3841062. DOI: 10.1016/j.cell.2013.09.053. View

Tse L, Klinc K, Madigan V, Castellanos Rivera R, Wells L, Havlik L . Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc Natl Acad Sci U S A. 2017; 114(24):E4812-E4821. PMC: 5474820. DOI: 10.1073/pnas.1704766114. View

Lokugamage M, Sago C, Dahlman J . Testing thousands of nanoparticles using DNA barcodes. Curr Opin Biomed Eng. 2019; 7:1-8. PMC: 6438390. DOI: 10.1016/j.cobme.2018.08.001. View

10.

Corti M, Elder M, Falk D, Lawson L, Smith B, Nayak S . B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol Ther Methods Clin Dev. 2014; 1. PMC: 4275004. DOI: 10.1038/mtm.2014.33. View

11.

. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489(7414):57-74. PMC: 3439153. DOI: 10.1038/nature11247. View

12.

Xu L, Wang J, Liu Y, Xie L, Su B, Mou D . CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia. N Engl J Med. 2019; 381(13):1240-1247. DOI: 10.1056/NEJMoa1817426. View

13.

Leborgne C, Barbon E, Alexander J, Hanby H, Delignat S, Cohen D . IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020; 26(7):1096-1101. DOI: 10.1038/s41591-020-0911-7. View

14.

Akinc A, Maier M, Manoharan M, FitzGerald K, Jayaraman M, Barros S . The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019; 14(12):1084-1087. DOI: 10.1038/s41565-019-0591-y. View

15.

Wu Y, Zeng J, Roscoe B, Liu P, Yao Q, Lazzarotto C . Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med. 2019; 25(5):776-783. PMC: 6512986. DOI: 10.1038/s41591-019-0401-y. View

16.

Pasi K, Rangarajan S, Mitchell N, Lester W, Symington E, Madan B . Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. N Engl J Med. 2020; 382(1):29-40. DOI: 10.1056/NEJMoa1908490. View

17.

Stadtmauer E, Fraietta J, Davis M, Cohen A, Weber K, Lancaster E . CRISPR-engineered T cells in patients with refractory cancer. Science. 2020; 367(6481). PMC: 11249135. DOI: 10.1126/science.aba7365. View

18.

Pickar-Oliver A, Gersbach C . The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019; 20(8):490-507. PMC: 7079207. DOI: 10.1038/s41580-019-0131-5. View

19.

Tebas P, Stein D, Tang W, Frank I, Wang S, Lee G . Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10):901-10. PMC: 4084652. DOI: 10.1056/NEJMoa1300662. View

20.

Shalem O, Sanjana N, Zhang F . High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet. 2015; 16(5):299-311. PMC: 4503232. DOI: 10.1038/nrg3899. View